MoonLake Immunotherapeutics
MLTX
115 hedge funds and large institutions have $3.43B invested in MoonLake Immunotherapeutics in 2024 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 31 reducing their positions, and 13 closing their positions.
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
55% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 31
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
32% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $8.56M
9% more capital invested
Capital invested by funds: $3.14B → $3.43B (+$294M)
6% more funds holding
Funds holding: 109 → 115 (+6)
1.55% more ownership
Funds ownership: 99.02% → 100.57% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$71M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$42.9M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$30.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.6M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$102M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.9M |
| 3 |
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne
Warszawa,
Poland
|
-$11.7M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$7.84M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.95M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
126
HRT Financial
New York
| – | -$685K | -13,592 | Closed |
|
127
Squarepoint
New York
| – | -$327K | -6,402 | Closed |
|
|
TRCT
128
Tower Research Capital (TRC)
New York
| – | -$84.3K | -1,672 | Closed |
|
|
SSG
129
Summit Securities Group
New York
| – | -$5K | -90 | Closed |
|
MLTX Hedge Fund Activity: Q4 2024 in Review
115 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q4 2024, worth a combined $3.43B — up 9.4% from $3.14B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new MLTX positions and 13 closed out — a net gain of 9 holders — while 48 added to existing stakes and 31 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $71M. The largest seller was BVF Inc, cutting an estimated $102M.
- 115 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q4 2024, up from 109 in Q3 2024.
- Funds reported $3.43B of MoonLake Immunotherapeutics stock for Q4 2024, up 9.4% quarter-over-quarter.
- 22 funds opened new MoonLake Immunotherapeutics positions in Q4 2024 and 13 closed out, a net change of +9 holders.
- The largest MoonLake Immunotherapeutics buyer in Q4 2024 was Fidelity Investments, an estimated $71M added.
- The largest MoonLake Immunotherapeutics seller in Q4 2024 was BVF Inc, an estimated $102M sold.
Based on aggregated 13F filings for Q4 2024.